AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2569050&ei=knKaUpjmBeTX0QGcJA&usg=AFQjCNGeshsc3_viqJ4pJFHO1YncqdDZXw
Amgen, Inc. Completes Acquisition of KAI Pharmaceuticals
Thursday, 5 Jul 2012 04:05pm EDT
Amgen, Inc. announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco. The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169, which is a agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Terms of the transaction were not disclosed.Â 
